Merck
RAHWAY, NJfiles as Merck & Co., Inc.
$526m in 13 US stocks at the end of 30 June 2026. The top 10 are 99.8% of the money. It changed about 16.0% of the portfolio this quarter.
Value
$526m
Stocks
13
Top 10 share
99.8%
Turnover
16.0%
What changed this quarter
New
Bought for the first time this quarter.
- Entrada TherapeuticsTRDA2.4% of the fund
- Sutro BiopharmaSTRO1.7% of the fund
- Evaxion ASEVAX0.7% of the fund
Added
Bought more of a stock they already held.
None this quarter.
Cut
Sold some of their stake.
None this quarter.
Sold out
Sold their entire stake.
- Entrada Therapeutics-100%
- Sutro BiopharmaSTRO-100%
- Evaxion Biotech A/S-100%
- Carisma TherapeuticsCARM-100%
Holdings
- Evaxion ASEVAX
- Share
- 0.7%
- Value
- $4m
- Shares
- 1,214,126
New
| Company | Share of fund | Value | Shares | Change |
|---|---|---|---|---|
| PersonalisPSNL | 35.8% | $188m | 14,044,943 | Held |
| ModernaMRNA | 30.7% | $162m | 2,308,190 | Held |
| Kymera TherapeuticsKYMR | 16.8% | $89m | 772,165 | Held |
| Aktis OncologyAKTS | 5.8% | $31m | 952,844 | Held |
| Eikon TherapeuticsEIKN | 4.1% | $22m | 1,666,666 | Held |
| Entrada TherapeuticsTRDA | 2.4% | $13m | 1,739,768 | New |
| Sutro BiopharmaSTRO | 1.7% | $9m | 272,351 | New |
| AlectorALEC | 1.4% | $7m | 3,545,719 | Held |
| Evaxion ASEVAX | 0.7% | $4m | 1,214,126 | New |
| Viridian TherapeuticsVRDN | 0.3% | $2m | 93,414 | Held |
| Xilio TherapeuticsXLO | 0.2% | $1m | 105,982 | Held |
| TuHURA BiosciencesHURA | <0.1% | $45,501 | 19,445 | Held |
| Neuphoria TherapeuticsNEUP | <0.1% | $43,818 | 10,027 | Held |
Over time and by industry
Value over time
Jun '25
Dec '25
Jun '26
Value is up 144.2% since 30 June 2025.
Where the money is
Health care99.3%
Other0.7%
From the fund's 13F filings. They list US stocks and options only, 45 days after each quarter, and leave out cash, bonds, shorts and foreign shares.